Login / Signup

The effects of empagliflozin on measured glomerular filtration rate and estimated extracellular and plasma volumes in patients with type 2 diabetes.

Mikkel JürgensMorten SchouPhilip HasbakAndreas KjaerEmil WolskBo ZerahnNiels Høegh Brandt-JacobsenPeter Haulund GaedeEllen BurgessJens FaberSilvio E InzucchiFinn GustafssonCaroline Kistorp
Published in: Diabetes, obesity & metabolism (2023)
Treatment with empagliflozin for 13 weeks reduced mGFR, estimated ECV and estimated PV in patients with T2D and high risk of cardiovascular events.
Keyphrases
  • cardiovascular events
  • coronary artery disease
  • cardiovascular disease
  • type diabetes
  • combination therapy
  • replacement therapy